Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Apr;17(4):e13805.
doi: 10.1111/cts.13805.

DPYD genotyping panels: Impact of population diversity

Guilherme Suarez-Kurtz  1
Affiliations
Comment

DPYD genotyping panels: Impact of population diversity

Guilherme Suarez-Kurtz. Clin Transl Sci. 2024 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declared no competing interests for this work.

Comment in

Comment on

References

    1. Turner AJ, Haidar CE, Yang W, et al. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clin Transl Sci. 2024;17(1):e13699. doi:10.1111/cts.13699 - DOI - PMC - PubMed
    1. CPIC® Guideline for Fluoropyrimidines and DPYD. https://cpicpgx.org/guidelines/guideline‐for‐fluoropyrimidines‐and‐dpyd/
    1. White C, Scott RJ, Paul C, et al. Dihydropyrimidine dehydrogenase deficiency and implementation of upfront DPYD genotyping. Clin Pharmacol Ther. 2022;112(4):791‐802. doi:10.1002/cpt.2667 - DOI - PubMed
    1. Suarez‐Kurtz G, Fernandes VC, Elias ABR. Implementation of DPYD genotyping in admixed American populations: Brazil as a model case. Clin Pharmacol Ther. 2023;114(1):23‐24. doi:10.1002/cpt.2921 - DOI - PubMed
    1. Amstutz U, Henricks LM, Offer SM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for Dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210‐216. doi:10.1002/cpt.911 - DOI - PMC - PubMed

LinkOut - more resources